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The sarcoglycan complex in muscle consists of α-, β-, γ- and δ-sarcoglycan and is part of the larger dystrophin–glycoprotein complex (DGC),
which is essential for maintaining muscle membrane integrity. Mutations in any of the four sarcoglycans cause limb-girdle muscular dystrophies
(LGMD). In this report, we have identified a novel interaction between δ-sarcoglycan and the 16 kDa subunit c (16K) of vacuolar H+-ATPase. Co-
expression studies in heterologous cell system revealed that 16K interacts specifically with δ-sarcoglycan and the highly related γ-sarcoglycan
through the transmembrane domains. In cultured C2C12 myotubes, 16K forms a complex with sarcoglycans at the plasma membrane. Loss of
sarcoglycans in the sarcoglycan-deficient BIO14.6 hamster destabilizes the DGC and alters the localization of 16K at the sarcolemma. In addition,
the steady state level of β1-integrin is increased. Recent studies have shown that 16K also interacts directly with β1-integrin and our data
demonstrated that sarcoglycans, 16K and β1-integrin were immunoprecipitated together in C2C12 myotubes. Since sarcoglycans have been
proposed to participate in bi-directional signaling with integrins, our findings suggest that 16K might mediate the communication between
sarcoglycans and integrins and play an important role in the pathogenesis of muscular dystrophy.
© 2007 Elsevier B.V. All rights reserved.Keywords: Sarcoglycan; Vacuolar ATPase; 16K; Muscular dystrophy; Integrin; BIO14.6 hamster1. Introduction
Sarcoglycans consists of a family of six single-pass transmem-
brane proteins, designatedα-,β-, γ-, δ-, ε- and ζ-SG [1–7]. γ-, δ-
and ζ-SG share significant sequence similarity while α-SG is
highly related to ε-SG. In skeletal muscle, α-,β-, γ- and δ-SG are
assembled into the sarcoglycan complex via a stepwise pathway
[8]. β-SG and δ-SG form a central core structure that is essential
for the assembly and targeting of the sarcoglycan complex to the
muscle membrane [9,10]. Mutations in the genes encoding any of
the four muscle sarcoglycans cause limb-girdle muscular
dystrophies (LGMD) type 2C-F, commonly known as sarcogly-Abbreviations: DG, dystroglycan; DGC, dystrophin–glycoprotein complex;
ECM, extracellular matrix; LGMD, limb-girdle muscular dystrophy; SG,
sarcoglycan; V-ATPase, vacuolar H+-ATPase
⁎ Corresponding author. Tel.: +1 570 271 6851; fax: +1 570 271 6701.
E-mail address: ymchan@geisinger.edu (Y.M. Chan).
0925-4439/$ - see front matter © 2007 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbadis.2007.01.014canopathies [2–4,11,12]. At the sarcolemma, the sarcoglycan
complex is part of the larger dystrophin–glycoprotein complex
(DGC), which provides a transmembrane linkage between the
actin cytoskeleton and the extracellular matrix (ECM) and is
critical formusclemembrane integrity [13]. The other members of
the DGC include dystrophin, α/β-dystroglycans, syntrophin,
dystrobrevin and sarcospan [14,15].
Currently, the function of sarcoglycans is not completely
understood. Genetic ablation of sarcoglycans in animal models
causes instability of the dystrophin-mediated transmembrane
linkage in muscle [16–19], suggesting that sarcoglycans play a
critical role in the stability of the DGC. Supporting this idea, we
have previously demonstrated that the β/δ-SG core interacts
with dystrophin [20]. Recently, sarcoglycan are also thought to
have non-structural functions, such as, bi-directional signaling
with integrins. It has been shown that sarcoglycans associate
with α5β1-integrin in rat L6 myocytes [21] and co-localize with
α7β1-integrin to costameres in human muscle fibers [22]. In
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the ECM. The proper maintenance of this integrin-mediated
transmembrane linkage is critical for muscle cell survival [23].
Mutations inα7-integrin have been reported to cause other forms
of muscular dystrophies in human [24] and animal models [25].
In support of the existence of a bi-directional communication
between sarcoglycans and integrins, several animal studies have
demonstrated a functional redundancy between the two com-
plexes for the maintenance of muscle membrane stability. For
example, α7-integrin is up-regulated in sarcoglycan-deficient γ-
SG-null mice [18]. Increased expression of α7β1-integrin in
muscle can reduce the dystrophic phenotypes in dystrophin-null
mdx mice [26]. Moreover, double knockout mice in both α7-
integrin and γ-SG (or dystrophin) develop severe muscle
degeneration and cause pre-mature death [18,27,28].
In this study, we searched for novel sarcoglycan-interacting
proteins with the hope of gaining insights into the function of the
sarcoglycan complex. Recently, a novel interaction between δ-SG
and the 16 kDa subunit c (16K) of the vacuolar H+-ATPase (V-
ATPase) has been documented in the protein interaction database
from CuraGen Corporation. The V-ATPase is a multi-subunit
protein complex that functions as an ATP hydrolysis driven
proton pump essential for acidification of intracellular compart-
ments. The complex is commonly found in endosomes and
lysosomes [29] but is also present on the cell surface to secrete
protons to the extracellular space in other highly specialized cell
types, including kidney tubule cells and osteoclasts [30]. We
demonstrated that a sub-population of 16K in C2C12myotubes is
localized at the plasma membrane and associates with the
sarcoglycan complex via the transmembrane and/or intracellular
domains. In addition to immunoprecipitate with 16K, sarcogly-
cans were also shown to immunoprecipitate with β1-integrin as
previously reported by Yoshida et al. [21]. In sarcoglycan-
deficient BIO14.6 hamsters, loss of the sarcoglycan complex
affects the localization of 16K but not the other subunits of V-
ATPase inmuscle.We also confirmed that theDGC is destabilized
[31] and the steady state level of β1-integrin is increased. Up-
regulation of integrins has been reported in animal models
deficient in sarcoglycans and in muscular dystrophy patients
[18,27,28,32]. Previous studies in L6 myoblasts have shown that
16K andβ1-integrin act coordinately independent of V-ATPase to
induce signals controlling cell adhesion [33–35]. In vitro binding
assay using epitope-tagged 16K andβ1-integrin revealed that they
can directly bind to each other [33]. Since we have demonstrated
that 16K also interacts with the sarcoglycan complex, it raises the
possibility that 16K is involved in mediating the communication
between sarcoglycans and integrins. The characterization of 16K
inmuscle and its interaction with the sarcoglycan complex should
generate novel insights into the molecular mechanisms under-
lying muscular dystrophy.2. Materials and methods
2.1. DNA constructs
Full-length cDNA encoding mouse α-, β-, γ-, or δ-SG was subcloned into
the pDEST mammalian expression vector (Invitrogen, Carlsbad, CA) aspreviously described [10]. HSV-tagged human 16K and the deletion mutant
(TM4) were described in a previous study [33].
2.2. Primary antibodies
Antibodies used in this study are listed in Supplementary Fig. 1. Rabbit
polyclonal antibodies against mouse γ-SG (ANA-γ) and 16K (AW-1) have been
previously described in other studies [20,36]. Rabbit polyclonal anti-16K
antibody (UGMS-1) was generated by Anaspec (San Diego, CA) using peptide
against human 16K sequence 36KSGTGIAAMSVMRPEQ51 in the extracellular
domain.
2.3. Animals
Male BIO14.6 Syrian hamsters and F1-B wild-type controls were purchased
from BioBreeders (Watertown, MA). Animals were maintained in the animal
facility according to guides outlined by the Association for Assessment and
Accreditation of Laboratory Animal Care International (AAALAC). Animal
studies were approved by the Geisinger Clinic Institutional Animal Care and
Use Committee (IACUC).
2.4. Cell culture and transient transfection
COS-1 cells and mouse C2C12 myoblasts were obtained from American
Type Culture Collection (Manassas, VA) and grown in DMEM (Mediatech,
Herndon, VA) supplemented with 10% fetal bovine serum (Invitrogen), 100 μg
ml−1 streptomycin, and 100 U ml−1 penicillin (Sigma, St. Louis, MO). Cell
cultures were incubated at 37 °C with 5% CO2. To induce differentiation into
myotubes, C2C12 myoblasts were grown to confluency and the media was
switched to DMEMsupplementedwith 2% horse serum (Invitrogen). Plates were
pre-coated with 20 μg ml−1 laminin (Sigma). Sarcoglycan and 16K constructs
were transiently transfected into COS-1 cells by Lipofect Amine reagent
(Invitrogen) according to the manufacturer's protocol. Transfected cells were
harvested 48 h post-transfection. 16K construct was transfected into C2C12
myoblasts using Nucleofactor technology developed by Amaxa (Gaithersburg,
MD). Transfected C2C12 myoblasts were switched to differentiation media 24 h
post-transfection and harvested 72 h later. Total proteins were extracted in M-
PER extraction buffer (Pierce, Rockford, IL) according to the manufacturer's
protocol. All extraction buffers used in this study contain 1x protease inhibitor
cocktail (Roche, Indianapolis, IN).
2.5. RT-PCR
Total RNA was extracted from mouse skeletal muscle, mouse kidney,
cultured C2C12 myotubes and rat cultured Schwann cells using the RNeasy
Mini Kit from QIAGEN according to the manufacturer's protocol (Valencia,
CA). The 16K PCR fragment was generated using primers (forward) 5′-
ACCCGCAGACATGTCCGAGT and (reverse) 5′-ACGAATAGTCG-
GGGCTGC at annealing temperature of 60 °C.
2.6. Muscle membrane preparation
Mouse skeletal muscle (400 mg) or C2C12 myotubes were homogenized by
a Potter-Elvehjem homogenizer on ice for 2 min with 4 ml of pyrophosphate
buffer (20 mM sodium pyrophosphate, 20 mM sodium phosphate, 1 mMMgCl2,
0.5 mM EDTA, and 10% sucrose, pH 7.1). The mixture was centrifuged at
500×g for 10 min at 4 °C to remove cell debris. The supernatant was then
centrifuged at 18000×g for 10 min to collect the pellet, which contains crude
membrane vesicles. Membrane proteins were extracted from the pellet with 2 ml
of TX-100 buffer (50 mM Tris pH 8.0, 150 mM NaCl, 1% Triton X-100, and
0.1% SDS).
2.7. Co-immunoprecipitation
Muscle membrane fraction or total cell lysate from cultured cells was first
pre-cleared with 20 μl of protein G-sepharose beads (Sigma) for 1 h at 4 °C. The
Fig. 1. Co-expression of HSV-tagged 16K and sarcoglycans. COS-1 cells were
co-transfected with (A) 16K-HSVand δ-SG, (B) 16K-HSVand γ-SG, (C) 16K-
HSVand β-SG, (D) 16K-HSVand α-SG, (E) 16K-HSVand K57X δ-SGmutant,
or (F) TM4-HSV mutant and δ-SG. (G) C2C12 myoblasts were transfected with
16K-HSV followed by differentiation into myotubes. Cell lysate was
immunoprecipitated using anti-HSV antibody (lane 2, A–F), anti-M5 antibody
as negative control (lane 3, A–F), or anti-γ-SG (ANA-γ) antibody (lane 4, G).
The immune complex was analyzed by Western blots using antibodies against
specific sarcoglycan, HSV-tag, and caveolin-3 as negative control. Lane 1, total
cell lysate (10 μg, 25% input); lanes 2–3, immunoprecipitated product (40 μg);
lane 4, immunoprecipitated product (200 μg).
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20 μl of protein G-sepharose beads for 1 h. The immune complex was collected
by centrifugation at 10000×g for 1 min and washed three times with 0.5 ml of
PBS with 0.1% Tween20. The final pellet was solubilized in 30 μl of protein
sample buffer (Invitrogen) and loaded on Novex pre-cast 4–20% SDS-PAGE
gels (Invitrogen). Co-immunoprecipitation experiments were performed three
times to confirm the results.
2.8. Immunofluorescent analysis
C2C12 myotubes were fixed in methanol at −20 °C for 10 min and treated
with 0.5% Triton X-100 in PBS for 10 min followed by blocking with 20%
normal goat serum in PBS. Cells were incubated with primary antibody in
blocking buffer overnight at 4 °C and then with secondary antibodies conjugated
with Alexa488 or Alexa594 for 1 h. Slides were mounted with Vectashield
medium and examined by Leica SP2 laser scanning microscope (Leica, Exton,
PA). Cells were sectioned into serial optical sections of 0.16 μm. Images were
processed with Leica confocal software.
2.9. Immunohistochemistry
Unfixed frozen sections (10 μm) of skeletal muscle were treated with 0.5%
Triton X-100 in PBS for 10 min followed by blocking with 20% normal goat
serum in PBS. Sections were stained with primary antibody diluted in the same
buffer for 2 h at room temperature followed by washing three times in PBS and
incubating with secondary antibodies conjugated with Alexa488 or Alexa594
(Invitrogen) for 1 h. After additional three 20-min washes in PBS, sections were
mounted on coverslips under Vectashield (Vector Laboratories). Slides were
examined by Nikon Eclipse E800 inverted fluorescence microscopy (Nikon,
Melville, NY) and photographed at 40× magnification using a CCD camera at
standard gain and exposure time. Images were processed by MetaMorph
Imaging System (Universal Imaging Corporation, Western Chester, PA).
2.10. Immunoelectron microscopy
Quadriceps femoris muscle from normal mouse was fixed in 0.1%
glutaraldehyde and 2% paraformaldehyde in PBS for 30 min. The specimen
was further trimmed into 2 mm stripes, washed with cool PBS, dehydrated
with cold alcohol and infiltrated with Lowicryl K4M medium (EM Sciences,
Hatfield, PA) at −25 °C. Samples were embedded in fresh Lowicryl K4M
and polymerized with UV light (365 nm) for 5 days at −25 °C. Ultrathin
sections were cut with a diamond knife, mounted on Formvar-coated Nickel
grids, incubated overnight at 4 °C with anti-16K antibody (UGMS-1),
followed by 15-nm gold-conjugated secondary antibody (Ted Pella, Redding,
CA). After 4 times wash with PBS, the sections were fixed with 2%
glutaraldehyde, and contrasted with uranyl acetate and lead citrate, and
analyzed with a FEI Tecnai-T12 electron microscope operated at 80 kV.
Digital images were captured with a Gatan 2K camera.
3. Results
3.1. Identification of 16K as a potential
sarcoglycan-interacting protein
Recent advances in bioinformatics have led to development
of numerous protein interaction databases. In order to identify
novel proteins that interact with sarcoglycans, we searched the
Drosophila Interaction Database from CuraGen Corporation.
This database documented more than 20000 protein inter-
actions derived from yeast two-hybrid screening of the Droso-
phila melanogaster genome [37]. These interactions were
further refined to approximately 5,000 interactions of high
confidence by a computational method in which the 16 kDa
subunit c of the vacuolar H+-ATPase (V-ATPase) was listed as apotential candidate to interact with the δ-SG homolog in Dro-
sophila. The V-ATPase complex is an ATP hydrolysis driven
proton pump essential for acidification of intracellular compart-
ments. It consists of a peripheral V1 domain and an integral
membrane V0 domain [29]. The 16 kDa subunit c (16K) has
four transmembrane helices (Supplementary Fig. 2) and forms a
hexamer in the V0 domain.
3.2. 16K interacts with δ-SG and γ-SG through the
transmembrane and intracellular domains
To confirm their interaction, we co-expressed δ-SG and 16K
in COS-1 cells and assessed their ability for association.
Although the sarcoglycan complex exists as a hetero-tetramer in
muscle, the interaction between a particular sarcoglycan subunit
and other proteins can be demonstrated by in vitro systems
without the presence of other sarcoglycan subunits. For
example, we have previously documented the interaction
between γ-sarcoglycan and filamin 2 using an in vitro cell-
free translation system [38]. We have also used this hetero-
logous expression system to investigate the interaction of
sarcoglycan subunits during the assembly process [10,20]. The
construct encoding 16K contains a C-terminal HSV-tag (16K-
HSV) to facilitate identification. As shown in Fig. 1A, the
association between the HSV-tagged 16K and δ-SG was
demonstrated by their co-immunoprecipitation using an anti-
HSVantibody. Similar result was obtained when 16K-HSV was
co-expressed with the highly related γ-SG, which shares 52%
sequence identity to δ-SG (Fig. 1B). Neither β-SG nor α-SG
was immunoprecipitated with 16K-HSV when co-expressed
individually with 16K (Fig. 1C–D). These findings suggest that
Fig. 2. Expression of 16K in muscle. (A) Detection of 16K transcripts by RT-
PCR in kidney (lane 1), skeletal muscle (lane 2), C2C12 myotubes (lane 3),
and Schwann cells (lane 4). (B) Detection of recombinant 16K-HSV in COS-1
cells (lanes 1–3), and endogenous 16K in C2C12 myotubes (lanes 4–5) by
Western blots using pre-immune serum (lanes 1, 4), anti-16K (UGMS-1)
antibody (lanes 2, 5), or anti-HSV antibody (lane 3). Note that 16K-HSV has a
MW of 22 kDa (arrow) due to the HSV-tag. Endogenous 16K has a MW of
16 kDa (arrowhead).
Fig. 3. Association of 16K with sarcoglycans in cultured myotubes. Membrane
fractions prepared from mouse C2C12 myotubes were incubated with anti-γ-SG
(ANA-γ) antibody (lane 2) or pre-immune serum (lane 3). The co-immuno-
precipitated product was identified by Western blots using antibodies against
16K, sarcoglycans, subunit F of V-ATPase (V-ATP F), syntrophin, dystrobrevin,
β-dystroglycan, dystrophin, and caveolin-3. Lane 1, membrane fraction (20 μg,
20% input); lanes 2–3, immunoprecipitated product (100 μg).
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the result of non-specific interaction between hydrophobic
transmembrane helices.
Our previous study has shown that the extracellular domain
is essential for the interaction of sarcoglycan subunits [20]. To
determine whether this region is required for interacting with
16K, we co-expressed 16K-HSV with the K57X δ-SG mutant,
which deletes the entire extracellular domain but retains the
transmembrane helix and intracellular tail. This truncated δ-SG
mutant was previously shown not to interact with other
sarcoglycan subunits in co-expression study [20]. As shown
in Fig. 1E, the K57X δ-SG mutant was still able to
immunoprecipitate with 16K-HSV, indicating that the trans-
membrane and intracellular domains of δ-SG are sufficient to
interact with 16K. To examine whether the transmembrane
domain of 16K is involved in interacting with δ-SG, we
generated a truncated deletion in 16K (TM4-HSV) lacking the
highly conserved 4th transmembrane domain and the short
cytoplasmic tail consisting of 6 amino acids (Supplementary
Fig. 2). The C-terminal HSV-tagged TM4 mutant was not
immunoprecipitated with δ-SG when they were co-transfected
together into COS-1 cells (Fig. 1F). Since the TM4-HSVmutant
is incorporated into hexamers with endogenous 16K [39], the
lack of binding of this mutant to δ-SG is likely not due to
altering the structure of 16K to the extent that it is incapable of
interacting with other proteins.
Given that sarcoglycans exist as tetramers in muscle, it is
important to demonstrate that their interaction with 16K occurs
under physiological environment where sarcoglycans form a
stable complex. To explore this issue, we transfected 16K-HSV
into C2C12 myoblasts and examined its interaction with
endogenous sarcoglycans during myotube formation. During
terminal differentiation, myoblasts are fused into myotubes ex-pressing characteristic muscle proteins, including sarcoglycans.
As shown in Fig. 1G, an anti-γ-SG antibody was able to
immunoprecipitate the recombinant 16K-HSV with endogenous
α-, β-, γ- and δ-SG from 3-day-old C2C12 myotubes. This anti-
γ-SG antibody was previously shown to immunoprecipitate α-,
β-, γ- and δ-SG as a stable complex from muscle lysate [20].
3.3. Expression of 16K in muscle
The expression of 16K in muscle was first determined by RT-
PCR. 16K transcripts were detected in skeletal muscle and
cultured C2C12 myotubes as well as non-muscle cells, such as
kidney and Schwann cells (Fig. 2A). This is consistent with the
broad pattern of 16K expression in many tissues. To confirm the
expression of 16K protein in muscle, we generated a rabbit
polyclonal antibody (UGMS-1) against its N-terminal extra-
cellular domain. On Western blot, both anti-HSV and anti-16K
antibodies recognized the HSV-tagged 16K expressed in COS-1
cells (Fig. 2B, lanes 2–3, arrow). When membrane fractions of
C2C12 myotubes were probed with the anti-16K antibody, a
specific immuno-reactive band at 16 kDa was observed (lane 5,
arrowhead), in agreement with its expected size. Western blot
using the anti-16K antibody showed that 16K is abundantly
expressed in brain and kidney (data not shown). Northern blot
analysis also reported a similar pattern of tissue distribution for
16K in a previous study [40].
3.4. Sarcoglycans associate with endogenous 16K in C2C12
myotubes
To verify the association of sarcoglycans with 16K in
muscle, we determined whether endogenous 16K can be
immunoprecipitated with sarcoglycans from cultured C2C12
myotubes. As shown in Fig. 3, 16K was immunoprecipitated
Fig. 4. Localization of 16K to the plasma membrane of C2C12 myotubes.
Cultured myotubes were co-stained with antibodies against 16K (UGMS-1) and
γ-SG (NCL-g-SARC) and analyzed by confocal microscopy. Confocal images
demonstrating plasma membrane staining of 16K (A, arrows) and γ-SG (B)
were taken from the same optical section. Co-localization of 16K and γ-SG at
the plasma membrane is demonstrated by yellow color (C, arrows). A different
optical section is shown to reveal cytoplasmic staining of 16K (D, arrowheads).
Bar, 20 μm.
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thus confirming the findings in co-expression studies. To
eliminate the possibility of non-specific binding of 16K to the
antibody, we showed that the anti-γ-SG antibody did not
immunoprecipitate recombinant 16K-HSV expressed in COS-1Fig. 5. Localization of 16K at the sarcolemma. Frozen cross-sections of mouse skel
Cross-section was stained with antibody against 16K (UGMS-1). (B) Identical cross-
image of panels A and B. Co-localization of 16K and γ-SG at the sarcolemma is dem
16K (UGMS-1). (E) Identical cross-section was co-stained with antibody against α
microscopy. (F) Cross-section was stained with a different anti-16K antibody (AW-1
25 μm in A–C, F; 18 μm in D–E.cells or endogenous 16K from kidney extract where γ-SG is not
present (Supplementary Fig. 3). Interestingly, the subunit F of
V-ATPase was not immunoprecipitated with sarcoglycans and
16K. Other members of the DGC, including syntrophin,
dystrobrevin, β-dystroglycan and dystrophin, were also not
detected in the immune complex, indicating that the interaction
between sarcoglycans and 16K occurs independent of other
DGC members. As a negative control, caveolin-3 was not
immunoprecipitated with sarcoglycans and 16K (Fig. 3). Since
caveolin-3 is a lipid raft component and do not interact directly
with the DGC, this ruled out the possibility that the association
of sarcoglycans with 16K is due to non-specific protein
aggregation.
3.5. Localization of 16K to the plasma membrane
Given the plasma membrane localization of sarcoglycans,
their interaction with 16K implies that 16K should be present on
the cell surface of C2C12 myotubes. When C2C12 myotubes
were co-stained with antibodies against 16K and γ-SG, both
16K and γ-SG were found to co-localize to the plasma
membrane by confocal microscopy (Fig. 4A–C). Interestingly,
16K staining was punctate and discontinuous along the plasma
membrane (arrows in A) whereas the membrane staining of γ-
SG from the same optical section was uniform (B). When
different optical sections were analyzed, distinct staining of 16K
was also observed in the cytoplasm (arrowheads in D), most
likely representing the V-ATPase complex in the intracellular
compartments. C2C12 myotubes were also treated with
membrane impermeable NHS-LC-biotin and 16K was shownetal muscle were co-stained with antibodies against 16K and sarcoglycans. (A)
section was co-stained with antibody against γ-SG (NCL-g-SARC). (C) Merged
onstrated by yellow color. (D) Cross-section was stained with antibody against
-SG (NCL-a-SARC). Images from panels D and E were analyzed by confocal
). Note the presence of cytoplasmic staining for 16K in panels A, D, and F. Bar,
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presence of 16K on the cell surface.
We then examined the sub-cellular localization of 16K in
muscle fibers. When cross-sections from mouse skeletal muscle
were co-stained with antibodies against 16K and γ-SG, 16K
was shown to co-localize with γ-SG at the sarcolemma (Fig.
5A-C). Labeling of 16K was also found in the cytoplasm (A).
Confocal microscopy revealed that the intensity of 16K labeling
varies in the muscle membrane and appears to concentrate in
localized regions (arrows in D), in contrast to the continuous
sarcolemmal staining displayed by sarcoglycans (Fig. 5E). This
pattern of staining is similar to what we observed for 16K in the
plasma membrane of C2C12 myotubes. Using a different anti-
16K antibody (AW-1) directed against the N-terminal cyto-
plasmic domain, similar patterns of sarcolemmal and cytoplas-
mic staining were detected for 16K in muscle cross-sections
(Fig. 5F). Moreover, immunoelectron microscopy studies also
showed specific labeling of 16K at the sarcolemma (Fig. 6A–
B, arrows) and in the intracellular space within myofibrils
(Fig. 6C, arrowhead). Together, these results suggest that there
are two pools of 16K in muscle: one at the sarcolemma asso-
ciated with sarcoglycans and the other within the cytoplasm.
3.6. Distribution of 16K at the sarcolemma is altered in
sarcoglycan-deficient hamsters
Within the DGC, the sarcoglycan complex is preferentially
associated with sarcospan, which belongs to the tetraspanFig. 6. Ultrastructural analysis of 16K localization in muscle fibers. Mouse skeletal m
microscopy. Labeling of 16K at the sarcolemma is demonstrated by the presence of 15
intracellular space within myofibrils (C, arrowhead). Mt denotes mitochondria. EC
plasma membrane and ECM. Bar, 0.4 μm in A, 0.15 μm in B, 0.25 μm in C.superfamily of transmembrane proteins [41]. Primary sarco-
glycan mutations in LGMD patients often leads to instability of
sarcospan at the sarcolemma [42]. To investigate whether the
absence of sarcoglycans has an adverse effect on 16K, which
also has four transmembrane helices, we analyzed the
expression and localization of 16K in sarcoglycan-deficient
BIO14.6 hamster, a widely used animal model for muscular
dystrophy and cardiomyopathy. The BIO14.6 hamster has a
deletion in the δ-SG gene [43,44]. The loss of δ-SG leads to
concomitant reduction of other sarcoglycan subunits and
instability of the DGC in muscle [16,17,31]. Immunofluor-
escent analysis of muscle cross-sections confirmed the absence
of the sarcoglycan complex in BIO14.6 hamsters as demon-
strated by near absent staining for α-SG at the sarcolemma
(Fig. 7B). Meanwhile, we noticed distinct accumulation of 16K
at the sarcolemma of BIO14.6 hamsters compared to that of
controls (Fig. 7D and F, arrows). In contrast, the staining
pattern of subunits F and G2 of the V-ATPase complex did not
change significantly (Fig. 7G–J). These results indicate that
loss of sarcoglycans specifically affects the 16K subunit in
muscle and raise the possibility that the interaction between
sarcoglycans and 16K does not involve the V-ATPase complex.
Interestingly, Western blot analysis showed that the steady state
levels of 16K in both control and BIO14.6 muscle membranes
were not noticeably different (Fig. 8A). The levels of
dystrophin and dystroglycans were reduced in the mutant
animals, consistent with the critical role of sarcoglycans in the
stability of the DGC.uscle was labeled with anti-16K (UGMS-1) antibody and analyzed by electron
-nm gold particles (A–B, arrows). Note that 16K labeling is also observed in the
M denotes extracellular matrix. Dashed lines represent the boundary between
Fig. 8. Expression of 16K and β1-integrin in sarcoglycan-deficient BIO14.6
hamsters. (A)Muscle membranes (40 μg) fromwild-type controls (lane 1) and δ-
SG−/− (BIO14.6) hamsters (lane 2) were analyzed by Western blots using
antibodies against 16K, β1-integrin, δ-SG, dystrophin, α-/β-dystroglycans,
sarcoglycans and caveolin-3 (negative control). Note that γ-SG was not shown
here since the anti-γ-SG antibodies did not recognize hamster γ-SG. (B)
Association of β1-integrin with 16K and sarcoglycans. Membrane fractions of
C2C12 myotubes (200 μg) were incubated with anti-β1-integrin (610467)
antibody. The immunoprecipitated product (lane 3) was identified by Western
blots using antibodies against 16K, sarcoglycans and β1-integrin. Pre-immune
serum (lane 4) was used as a negative control for co-immunoprecipitation.
Fig. 7. Localization of 16K in sarcoglycan-deficient BIO14.6 hamsters. Skeletal muscle cross-sections of wild-type controls (A, C, E, G, I, K) and δ-SG−/− (BIO14.6)
hamsters (B, D, F, H, J, L) were stained with antibodies against α-SG (A–B), 16K (C–F), V-ATP F (G–H), V-ATP G2 (I–J), and β1-integrin (7E2) (K–L). Panels C–D
and E–F represent muscle biopsy taken from tricep brachii and quadriceps femoris of two different hamsters, respectively. Note that 16K in δ-SG−/− hamsters forms
distinct aggregates at the sarcolemma (arrows in D and F). Five hamsters, ranging from 12 weeks to 36 weeks old, were analyzed and representative pictures are shown.
Bar, 35 μm.
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sarcoglycan complex
Previous reports have demonstrated the up-regulation of α7-
integrin in the absence of sarcoglycans [18] or the DGC [32].
Consistent with these findings, we have observed an increased
level of β1-intergrin in BIO14.6 hamsters. The immunofluor-
escent staining for β1-intergrin at the sarcolemma was more
intense in BIO14.6 hamsters (Fig. 7L). The increased expres-
sion of β1-intergrin was confirmed by Western blots (Fig. 8A).
Thus, our data provide additional evidence to support the
proposed role of α7β1-integrin in compensating the sarcoglycan
complex for the maintenance of the transmembrane linkage in
skeletal muscle. In light of these results, it is important to
mention that 16K can also bind directly to β1-integrin [33–35].
This raises the possibility of a higher-order association among
16K, sarcoglycans and integrins. To explore this issue, we
performed co-immunoprecipitation of C2C12 myotube mem-
brane fractions using an anti-β1-intergrin antibody and showed
that 16K, α-SG, β-SG, γ-SG, and δ-SG were immunoprecipi-
tated together with β1-intergrin (Fig. 8B).
4. Discussion
In order to elucidate the function of the sarcoglycan complex
in muscle, we searched for novel sarcoglycan-interacting
proteins. In the present study, we reported a novel interaction
between sarcoglycans and the 16 kDa subunit c of the vacuolar
577J. Chen et al. / Biochimica et Biophysica Acta 1772 (2007) 570–579H+-ATPase through database searching. Our results demon-
strated that 16K interacts specifically with δ-SG and the highly
related γ-SG through the transmembrane and/or intracellular
domains. Although the sarcoglycan complex is part of the larger
DGC, its interaction with 16K in C2C12 myotubes does not
appear to require other critical members of the DGC. The
absence of other DGC components in the immune complex is
most likely due to the possibility that the anti-γ-SG antibody
used in this study selectively dissociates sarcoglycans from
other DGC components during immunoprecipitation [20].
Yoshida et al. has also shown that the sarcoglycan complex
can be dissociated from other DGC components under certain
conditions, such as in the presence of n-octyl β-D-glucoside
[45]. In addition, there are several lines of evidence to suggest
that the interaction between sarcoglycans and 16K is also
independent of V-ATPase. Previous studies have reported that
16K can form structures outside V-ATPase, including gap
junction complex in Drosophila [46] and neurotransmitter
release channel [47]. In this study, the subunit F of V-ATPase,
which is in direct contact with 16K in the V-ATPase complex,
was not immunoprecipitated with sarcoglycans. In addition,
localization studies revealed the existence of a sub-population
of 16K at sarcolemma where it associates with sarcoglycans.
Subcellular fractionation experiments also showed that δ-SG
was enriched with 16K but not the subunit F in the sarcolemmal
fractions (data not shown). Interestingly, 16K staining along the
plasma membrane of C2C12 myotubes is discontinuous and
does not completely co-localize with sarcoglycans, indicating
that 16K is absent in areas where sarcoglycans are present. As a
result, sarcoglycans are not always complexed with 16K and
this might account for the observation that the anti-γ-SG
antibody did not efficiently immunoprecipitate endogenous
16K in C2C12 myotubes. Finally, loss of the sarcoglycan
complex in BIO14.6 hamsters specifically disrupts the localiza-
tion of 16K at the sarcolemma but has no effect on the other
subunits of V-ATPase. Other proteins known to interact with
sarcoglycans, such as sarcospan and filamin C, also display
altered localization patterns in sarcoglycan-deficient animal
models [38,41]. The abnormal localization and expression of
these sarcoglycan-interacting proteins might contribute, at least
in part, to the cellular defects underlying LGMD.
Although sarcoglycans are critical for the stability of the
DGC, recent studies have suggested that sarcoglycans might
communicate with integrins in mediating cell adhesion to the
ECM [21]. It has been proposed that up-regulation of α7β1-
integrin might be a compensatory mechanism for the
disruption of the DGC-mediated transmembrane linkage in
muscle [18,26–28]. Consistent with this idea, α7-integrin has
been shown to up-regulate in the absence of sarcoglycans or
the DGC [18,32]. The level of β1-integrin is also increased in
the skeletal muscle of sarcoglycan-deficient BIO14.6 hamsters
as reported in the current study. Since 16K can interact with
β1-integrin [33–35] as well as δ-SG/γ-SG as documented in
this study, we propose that 16K might play an important role
in mediating the communication between sarcoglycans and
integrins. It is conceivable that these molecules could form a
tertiary complex at the sarcolemma where both sarcoglycan-and integrin-mediated transmembrane linkages interact toge-
ther with laminin in the ECM to strengthen muscle cell
adhesion and to withstand larger mechanical force. In support
of this hypothesis, a previous study has documented the co-
localization of α7β1-integrin and sarcoglycans in costamere
[22,48], which is sub-membrane specialization along Z disk
essential for force transduction from myofibrils to sarcolemma
[49]. In L6 myotubes, α-sarcoglycan, α5β1-integrin and
vinculin exhibited overlapping distribution at the plasma
membrane, especially at focal adhesion-like spotty structures
[21]. Immunofluorescent analysis also revealed that 16K and
β1-integrin were co-localized in focal adhesions [33]. Con-
sistent with these findings, we demonstrated that sarcoglycans,
16K and β1-integrin were immunoprecipitated together in
C2C12 myotubes.
In light of these results, it is important to mention that 16K is
involved in regulating the expression and glycosylation of β1-
integrin in a V-ATPase-independent manner [34]. It has been
shown that the assembly of integrins is dependent on their
interaction with the chaperon protein calnexin in ER [50] and
that overexpression of 16K in human fibrosarcoma HT180 cells
down-regulates surface expression of β1-integrin through
inhibition of β1-integrin binding to calnexin [35]. As shown
in this study, the disruption of the sarcoglycan complex in
BIO14.6 hamsters causes mis-localization of 16K at the
sarcolemma although the cellular mechanism remains to be
determined. It is tempting to speculate that there would be less
16K available to bind to β1-integrin such that more β1-integrin
can associate with calnexin, leading to its increased expression
on the cell surface. This could allow sarcoglycans to
communicate and influence integrins through 16K. In this
respect, 16K functions as a shuttle molecule in transmitting
cellular information between the sarcoglycan and integrin
complexes.
16K could also participate in other essential cellular
functions. For example, the V0 domain is thought to play a
direct role in membrane fusion independent of the proton
pumping mechanism [51]. In situ hybridization in E17 and E20
rat embryos has demonstrated that the expression of 16KmRNA
becomes more restricted to the myoblasts that are in the process
of fusion [52]. In addition, 16K forms a complex with the E5
oncoprotein of papillomaviruses and has been proposed to
mediate the ability of E5 to cause ligand-independent activation
of the PDGF-β receptor [39]. It is possible that 16Kmight recruit
membrane-bound growth factors and signaling molecules and
facilitate assembly of signaling complexes by tethering these
molecules to sarcoglycans. Thus, mis-localization of 16K could
potentially disrupt signaling pathways essential for muscle cell
function and survival.
In summary, the identification of 16K as a novel sarcoglycan-
interacting protein should generate novel insights into the
pathogenesis of muscular dystrophy. Since 16K-null mice are
embryonic lethal [53], a conditional knockout of 16K is
necessary to address the precise function of 16K in muscle and
to elucidate the functional significance of its interaction with
sarcoglycans and α7β1-integrin. This would provide new
directions into the development of new pharmacological
578 J. Chen et al. / Biochimica et Biophysica Acta 1772 (2007) 570–579agents for compensating sarcoglycan function in muscular
dystrophy.
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